Safety and Effectiveness of Pradaxa Oral Pellet Formulation for Treatment of Acute Venous Thromboembolic Events (VTE) and/or for Risk Reduction of Recurrence of VTE in Pediatric Patients Aged 3 Months to Less Than 12 Years in a Real World Setting: a Prospective Non-interventional Study Conducted in the United States
Latest Information Update: 09 May 2025
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 01 May 2025 Status changed from active, no longer recruiting to completed.
- 11 Apr 2025 Planned End Date changed from 3 Nov 2026 to 30 Apr 2025.
- 11 Apr 2025 Planned primary completion date changed from 3 Nov 2026 to 30 Apr 2025.